Darko Kastelan

Prof. Dr. Darko Kastelan

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 August 2022 in Journal Of Hypertension
Verified
Journal Article
Open access
FFFrancesco Fallo
Francesco Fallo
GDGuido Di Dalmazi
Guido Di Dalmazi
FBFelix Beuschlein
Felix Beuschlein
NBNienke R. Biermasz
Nienke R. Biermasz
FCFrederic Castinetti
Frederic Castinetti
MPMartin Reincke Prof
Martin Reincke Prof
Endogenous/exogenous Cushing's syndrome is characterized by a cluster of systemic manifestations of hypercortisolism, which cause increased cardiovascular risk. Its biological basis is glucocorticoid excess, acting on various pathogenic processes inducing cardiovascular damage. Hypertension is a common feature in Cushing's syndrome and may persist after normalizing hormone excess and discontinuing steroid therapy. In endogenous Cushing's syndrome, the earlier the diagnosis the sooner management can be employed to offset the deleterious effects of excess cortisol. Such management includes combined treatments directed against the underlying cause and tailored antihypertensive drugs aimed at controlling the consequences of glucocorticoid excess. Experts on endocrine hypertension and members of the Working Group on Endocrine Hypertension of the European Society of Hypertension (ESH) prepared this Consensus document, which summarizes the current knowledge in epidemiology, genetics, diagnosis, and treatment of hypertension in Cushing's syndrome.

7 February 2023 in European Journal of Endocrinology
Verified
Journal Article
Open access
PDF file
VAVincent Amodru
Vincent Amodru
AFAmandine Ferriere
Amandine Ferriere
ATAntoine Tabarin
Antoine Tabarin
FCFrederic Castinetti
Frederic Castinetti
STStylianos Tsagarakis
Stylianos Tsagarakis
EVElena Valassi
Elena Valassi
Objective: To evaluate whether age-related differences exist in clinical characteristics, diagnostic approach, and management strategies in patients with Cushing's syndrome (CS) included in the European Registry on Cushing's Syndrome (ERCUSYN).Design: Cohort study.Methods: We analyzed 1791 patients with CS, of whom 1234 (69%) had pituitary-dependent CS (PIT-CS), 450 (25%) adrenal-dependent CS (ADR-CS), and 107 (6%) had an ectopic source (ECT-CS). According to the WHO criteria, 1616 patients (90.2%) were classified as younger (<65 years old) and 175 (9.8%) as older (≥65 years old).Results: Older patients were more frequently males and had a lower Body Mass Index (BMI) and waist circumference when compared with the younger. Older patients also had a lower prevalence of skin alterations, depression, hair loss, hirsutism, and reduced libido, but a higher prevalence of muscle weakness, diabetes, hypertension, cardiovascular disease, venous thromboembolism, and bone fractures than younger patients, regardless of sex (P < .01 for all comparisons). Measurement of urinary free cortisol supported the diagnosis of CS less frequently in older patients when compared with the younger (P < .05). An extrasellar macroadenoma (macrocorticotropinoma with extrasellar extension) was more common in older PIT-CS patients than in the younger (P < .01). Older PIT-CS patients more frequently received cortisol-lowering medications and radiotherapy as a first-line treatment, whereas surgery was the preferred approach in the younger (P < .01 for all comparisons). When transsphenoidal surgery was performed, the remission rate was lower in the elderly when compared with their younger counterpart (P < .05).Conclusions: Older CS patients lack several typical symptoms of hypercortisolism, present with more comorbidities regardless of sex, and are more often conservatively treated.

Verified
Journal Article
Open access
PDF file
VBVittoria Basile
Vittoria Basile
Soraya PuglisiSoraya Puglisi
Soraya Puglisi
BABarbara Altieri
Barbara Altieri
Letizia CanuLetizia Canu
Letizia Canu
RLRossella Libè
Rossella Libè
Massimo TerzoloMassimo Terzolo
Massimo Terzolo
A relevant issue on the treatment of adrenocortical carcinoma (ACC) concerns the optimal duration of adjuvant mitotane treatment. We tried to address this question, assessing whether a correlation exists between the duration of adjuvant mitotane treatment and recurrence-free survival (RFS) of patients with ACC. We conducted a multicenter retrospective analysis on 154 ACC patients treated for ≥12 months with adjuvant mitotane after radical surgery and who were free of disease at the mitotane stop. During a median follow-up of 38 months, 19 patients (12.3%) experienced recurrence. We calculated the RFS after mitotane (RFSAM), from the landmark time-point of mitotane discontinuation, to overcome immortal time bias. We found a wide variability in the duration of adjuvant mitotane treatment among different centers and also among patients cared for at the same center, reflecting heterogeneous practice. We did not find any survival advantage in patients treated for longer than 24 months. Moreover, the relationship between treatment duration and the frequency of ACC recurrence was not linear after stratifying our patients in tertiles of length of adjuvant treatment. In conclusion, the present findings do not support the concept that extending adjuvant mitotane treatment over two years is beneficial for ACC patients with low to moderate risk of recurrence.

1 August 2015 in European Journal of Endocrinology
Verified
Journal Article
Closed access
PDF file
DKDarko Kastelan
Darko Kastelan
IKIvana Kraljević
Ivana Kraljević
TDTina Dusek
Tina Dusek
NKNikola Knezevic
Nikola Knezevic
MSMirsala Solak
Mirsala Solak
ZKZeljko Kastelan
Zeljko Kastelan
Objective The current guidelines for the management of adrenal incidentaloma advise hormonal and radiological follow-up of patients for 2–5 years after the initial diagnosis. However, the vast majority of adrenal incidentaloma are non-functional benign cortical adenomas that require no treatment, so the routine application of the current strategies often results in a number of unnecessary biochemical and radiological investigations. The aim of this study was to analyse the clinical course of patients with adrenal incidentaloma and to provide a critical review of the current management strategy of the disease. Design and methods This was a retrospective study performed in the Croatian Referral Center for adrenal gland disorders. The study included 319 consecutive patients with adrenal incidentaloma, 174 of which were followed for at least 24 months. Results The vast majority of patients were diagnosed with benign adrenal masses, whereas in about 5% of them adrenal tumor corresponded to adrenal carcinoma or metastasis. Tumor density was found to be superior to tumor size in distinguishing benign adrenal masses from malignant tumors and pheochromocytomas. During the follow-up, no patient demonstrated a clinically significant increase in tumor size. In addition, no changes, either in metanephrines and normetanephrines or in the activity of renin–aldosterone axis, were observed during the follow-up. Six patients developed subclinical Cushing's syndrome (SCS) whereas eight patients with SCS showed biochemical remission during follow-up. Conclusion The study suggests that the risk of an adrenal mass initially diagnosed as benign and non-functional becoming malignant or hormonally active is extremely low. Therefore, the clinical management of those patients should be tailored on an individual basis in order to avoid unnecessary procedures.

20 June 2022 in Journal of Neuroendocrinology
Verified
Journal Article
Closed access
ABAnnemarie Balasko
Annemarie Balasko
KTKarin Zibar Tomsic
Karin Zibar Tomsic
DKDarko Kastelan
Darko Kastelan
TDTina Dusek
Tina Dusek

18 May 2020 in Clinical Endocrinology
Verified
Journal Article
Closed access
PDF file
DKDarko Kastelan
Darko Kastelan
NKNikola Knezevic
Nikola Knezevic
KTKarin Zibar Tomsic
Karin Zibar Tomsic
AAAna‐Marija Alduk
Ana‐Marija Alduk
LKLuka Kakarigi
Luka Kakarigi
TDTina Dusek
Tina Dusek